Spigel D, et al. Impower110: interim overall survival (OS) analysis of a phase 3 study of atezolizumab (atezo) versus platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC. ESMO Congress 2019, abstract LBA78.
Tucatinib verlengt mediane overleving met 5,5 maand in finale analyse HER2CLIMB-studie
mrt 2022 | Borstkanker